House	Amendment NO
	Offered By
	ee Substitute for Senate Substitute for Senate Bill No. 7, Page 87, Section rting after said section and line the following:
" <u>376.417. 1. As ı</u>	used in this section, the following terms mean:
(1) "340B drug",	the same meaning given to the term in section 376.414;
(2) "Covered enti	ty", any entity described in subparagraphs (A) to (K) of subsection (a)(4)
of Section 340B of the Pu	blic Health Service Act, 42 U.S.C. Section 256b, including any pharmacy
with which such entity ha	s contracted to dispense 340B drugs on behalf of the entity;
(3) "Health carrie	r", the same meaning given to the term in section 376.1350;
(4) "Pharmacy", a	un entity licensed under chapter 338;
(5) "Pharmacy be	nefits manager", the same meaning given to the term in section 376.388.
2. A health carrie	r, a pharmacy benefits manager, or an agent or affiliate of such health
carrier or pharmacy benef	its manager shall not discriminate against a covered entity including, but
not limited to, by doing an	ny of the following:
(1) Reimbursing	a covered entity for a quantity of a 340B drug in an amount less than it
would pay any other simi	larly situated pharmacy or entity that is not a covered entity for such
quantity of such drug on t	he basis that the covered entity is a covered entity or that the covered
entity dispenses 340B dru	gs. The director of the department of commerce and insurance shall
specify by rule the circum	astances under which a pharmacy or entity shall be deemed a "similarly
situated pharmacy or entit	ty" for purposes of this subdivision;
(2) Imposing any	terms or conditions on covered entities that differ from such terms or
conditions applied to othe	er similarly situated entities or pharmacies that are not covered entities on
the basis that the covered	entity is a covered entity or that the covered entity dispenses 340B drugs
including, but not limited	to, terms or conditions with respect to any of the following:
(a) Fees, chargeba	acks, clawbacks, adjustments, or other assessments;
(b) Professional d	ispensing fees;
(c) Restrictions of	r requirements regarding participation in standard or preferred pharmacy
networks;	
(d) Requirements	relating to the frequency or scope of audits or to inventory management
systems using generally a	ccepted accounting principles; and
Action Taken	Date

- (e) Any other restrictions, conditions, practices, or policies that, as specified by the director of the department of commerce and insurance, interfere with the ability of a covered entity to maximize the value of discounts provided under 42 U.S.C. Section 256b;
- (3) Discriminating in reimbursement to a covered entity based on the determination or indication a drug is a 340B drug;
- (4) Requiring a covered entity to identify, either directly or through a third party, a 340B drug;
 - (5) Refusing to cover drugs purchased under the 340B drug-pricing program; or
- (6) Requiring a covered entity to reverse, resubmit, or clarify a 340B drug-pricing claim after the initial adjudication unless these actions are:
 - (a) In the normal course of pharmacy business and not related to 340B drug pricing; or
- 12 <u>(b) Required by federal law.</u>

1 2

- 3. The director of the department of commerce and insurance shall impose a civil penalty on any health carrier, pharmacy benefits manager, or agent or affiliate of such health carrier or pharmacy benefits manager that violates the requirements of this section. Such penalty shall not exceed five thousand dollars per violation per day.
- 4. The director of the department of commerce and insurance shall promulgate rules to implement the provisions of this section. Any rule or portion of a rule, as that term is defined in section 536.010, that is created under the authority delegated in this section shall become effective only if it complies with and is subject to all of the provisions of chapter 536 and, if applicable, section 536.028. This section and chapter 536 are nonseverable and if any of the powers vested with the general assembly pursuant to chapter 536 to review, to delay the effective date, or to disapprove and annul a rule are subsequently held unconstitutional, then the grant of rulemaking authority and any rule proposed or adopted after August 28, 2025, shall be invalid and void."; and

Further amend said bill by amending the title, enacting clause, and intersectional references accordingly.